|
KMID : 0939920220540020488
|
|
대한암학회지
2022 Volume.54 No. 2 p.488 ~ p.496
|
|
|
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
|
|
Kim Jung-Sun
Suh Koung-Jin
Lee Dae-Won
Woo Go-Un
Kim Mi-So
Kim Se-Hyun
Ryu Han-Suk
Lee Kyung-Hun
Kim Tae-Yong
Han Sae-Won
Park So-Yeon
Park In-Ae
Kim Jee-Hyun
Im Seock-Ah
|
|
|
Abstract
|
|
|
Purpose: We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods: This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane) between March 2016 and March 2020 were enrolled.
Results: A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2?positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion: This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.
|
|
|
KEYWORD
|
|
|
Albumin-bound paclitaxel, Breast neoplasms, Neoplasm metastasis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|